LeMaitre Vascular, Inc. $LMAT Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC reduced its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 13.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 79,062 shares of the medical instruments supplier’s stock after selling 12,721 shares during the quarter. ProShare Advisors LLC’s holdings in LeMaitre Vascular were worth $6,566,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Alps Advisors Inc. purchased a new stake in LeMaitre Vascular in the first quarter valued at approximately $354,000. Mutual of America Capital Management LLC grew its stake in shares of LeMaitre Vascular by 6.1% in the first quarter. Mutual of America Capital Management LLC now owns 35,331 shares of the medical instruments supplier’s stock valued at $2,964,000 after buying an additional 2,038 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of LeMaitre Vascular by 45.9% in the 1st quarter. Victory Capital Management Inc. now owns 79,871 shares of the medical instruments supplier’s stock valued at $6,701,000 after buying an additional 25,133 shares during the period. Segall Bryant & Hamill LLC raised its holdings in shares of LeMaitre Vascular by 29.4% in the 1st quarter. Segall Bryant & Hamill LLC now owns 76,460 shares of the medical instruments supplier’s stock valued at $6,415,000 after buying an additional 17,354 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in LeMaitre Vascular during the 1st quarter worth about $728,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $89.64 on Friday. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The firm’s fifty day simple moving average is $89.09 and its 200-day simple moving average is $87.00. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of 43.51, a PEG ratio of 2.29 and a beta of 0.77. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm had revenue of $61.05 million during the quarter, compared to the consensus estimate of $62.18 million. During the same quarter in the previous year, the firm posted $0.49 earnings per share. The company’s revenue was up 11.4% compared to the same quarter last year. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. Equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 4th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, November 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.48%.

Analysts Set New Price Targets

Several analysts have recently issued reports on LMAT shares. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Wednesday, October 8th. Roth Capital reissued a “buy” rating and issued a $108.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, November 5th. Barrington Research restated an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Finally, Wells Fargo & Company reduced their price objective on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.